Background Evidence is available on the eff ectiveness and costs of treatments to reduce stroke risk in long-term secondary prevention. However, there are few data on the costs and outcomes of urgent assessment and treatment after the onset of transient ischaemic attack (TIA) or minor stroke. The Early use of eXisting PREventive Strategies for Stroke (EXPRESS) study showed that urgent assessment and treatment reduced the 90-day risk of recurrent stroke by about 80%. We now report the eff ect of the EXPRESS intervention on admissions to hospital, costs, and disability.
Introduction
Stroke is the second leading cause of death worldwide; it accounts for 10% of total deaths, 1 and is one of the main reasons for use of health-care resources 2 at an annual cost to the UK health-care system of £4·6 billion. 3 Treatments have been developed to prevent recurrent strokes in the long term after a transient ischaemic attack (TIA) or minor stroke; [4] [5] [6] [7] [8] appropriate interventions are predicted to reduce the long-term risk of recurrent stroke by as much as 80-90%. 9 However, although the risk of recurrent stroke is 8-10% during the 7 days after a TIA or minor stroke, [10] [11] [12] until recently there were no reliable estimates of the eff ectiveness, let alone costs, of rapid assessment and acute treatment for such patients. In the UK, which has relatively low rates of hospital admissions for TIA and minor stroke, 13 this could entail emergency access to outpatient specialist care because about half of all patients currently wait more than 14 days to be assessed and treated. 14 The aim of the Early use of eXisting PREventive Strategies for Stroke (EXPRESS) study was to measure the eff ect of more rapid treatment after TIA and minor stroke in patients who were not admitted directly to hospital. 15 EXPRESS was a rigorous observational study of the phased introduction of urgent assessment and treatment, nested within a population-based study of all incident and recurrent TIA and stroke in Oxfordshire, UK (the Oxford Vascular Study [OXVASC] ). 16 During phase 1 of OXVASC, a daily TIA and minor stroke clinic was introduced, to which collaborating primary-care physicians referred most patients with suspected TIA or minor stroke. The clinic was appointment based, and there were inherent delays in receiving referrals and contacting patients; furthermore, instead of initiating treatment, the clinic only made treatment recommendations to the referring primary-care physicians. After 30 months, the clinic was changed to a "no appointment necessary" clinic, to which primary-care physicians were asked to send all patients immediately after presentation for TIA or minor stroke, and treatment was initiated immediately if the diagnosis was confi rmed (phase 2). The EXPRESS study showed that the 90-day risk of recurrent stroke fell by about 80% in patients who were referred to the phase 2 clinic compared with those referred to the phase 1 clinic (10·3% in phase 1 vs 2·1% in phase 2; p=0·0001). This benefi t was independent of age and sex, and early treatment did not increase the risk of major bleeding. Similar low risks of recurrent stroke with urgent assessment and treatment have also been reported in the SOS-TIA study. 17 The objective of this study was to assess to what extent the reduction in recurrent stroke risk in phase 2 of EXPRESS, compared with phase 1, reduced admissions to hospital, the number of bed-days, costs associated with admission to hospital, and disability in those patients referred to the EXPRESS TIA and minor stroke outpatient clinic. This information will supply health-care providers with the necessary data to consider a similar service provision for patients with TIA and minor stroke.
Methods

Patients
The methods of OXVASC and EXPRESS have been reported previously. 15, 16 The OXVASC study population comprised about 91 000 individuals who were registered at nine primary-care practices across Oxfordshire, UK. Registration of patients into the study began on April 1, 2002 (phase 1). Informed, formal, written consent was obtained from all patients included in the analyses.
Procedures
The EXPRESS study was a population-based sequential comparison study nested within OXVASC. Phase 1 ran from April 1, 2002, to Sept 30, 2004 , during which time primary-care physicians referred any patient who was suspected of having a TIA or non-disabling stroke to the study clinic. The OXVASC team then contacted the patient to arrange a clinic appointment as quickly as possible. After clinic assessment and investigation, the general practitioner was faxed a report that included any treatment recommendations. In phase 2 (Oct 1, 2004, to March 31, 2007), the mode of access to the outpatient clinic was changed, and treatment was initiated in the clinic. Primary-care physicians were requested to send all patients directly to the study clinic immediately after they presented for medical attention, with no need to prearrange referral, and treatment was initiated immediately in the clinic. In both phases, the study clinician recorded detailed clinical information and the modifi ed Rankin scale (mRS) score 18 before the event. Neurological impairment was measured with the National Institutes of Health stroke scale (NIHSS), 19 to assess the severity of an event at baseline. As reported previously, 15 the protocols for investigation and the treatments recommended were identical in both phases of the study, except that treatment was initiated in the study clinic in phase 2.
All patients were followed up by a research nurse or clinical research fellow at 1 and 6 months after the index event, and patients were asked about any new neurological symptoms or any bleeding that required medical attention, with patients being reassessed with the mRS. Recurrent vascular events were also identifi ed acutely by overlapping methods of hot and cold pursuit. 20 All patients with possible recurrent strokes were reassessed by a study neurologist (PMR or colleagues), 15 who prepared a detailed clinical report of the event and related investigations. These reports were all reviewed at the end of the study by an independent neurologist who was blind to the phase of the study in which the event occurred and who decided which events were defi nite recurrent strokes. 15 
Statistical analysis
The primary analysis included all patients with TIA or stroke referred to the EXPRESS study clinic until March 31, 2007 (ie, during phases 1 and 2 of the EXPRESS study), with follow-up to June 30, 2007 . A sensitivity analysis was also done for all patients with TIA or minor stroke (NIHSS score ≤3 points) in the whole OXVASC population, irrespective of whether they were referred to the EXPRESS study clinic or to other services.
As was detailed in the original report of the EXPRESS study, 15 the exclusion of patients from the analysis in phase 2 if they had also presented in phase 1 could have caused bias (patients were not excluded from phase 1 if they had an event before the study); therefore, patients who presented in both phases were included in both analyses. The same approach was used in this study. To avoid any possible bias due to carry-over eff ects of improved long-term treatment in phase 1 (compared with treatment before the study) on outcome of any subsequent events in phase 2, all analyses in the original report of the EXPRESS study were also done for incident fi rst-ever events only. However, because there were no qualitative diff erences between these analyses and the overall results, analysis of only incident events was not repeated in this study.
The primary outcome in the EXPRESS study was the 90-day risk of recurrent stroke. 15 Outcome measures included in this further analysis were hospital admissions, days in hospital, total costs of admission to hospital during the 90 days after the event, and new patient disability or death. For any patient who was admitted to hospital before the 90-day follow-up but who was in hospital beyond this time period, length of stay was estimated until hospital discharge. All-cause admissions to hospital (ie, for TIA, stroke, or other vascular and non-vascular diseases) and hospital bed-days were assessed. For admissions to hospital due to vascular reasons, a more in-depth analysis was done by examination of overall days in hospital, length of stay conditional on admission, and costs, stratifi ed by those incurred by recurrent stroke and those incurred by other vascular causes. Our study, however, did not include the costs of setting up the outpatient clinics for the urgent assessment and treatment of TIA and minor stroke. Because the phase 2 clinic was nested within the ongoing OXVASC study, which already operated a daily study clinic, it was not possible to quantify the additional costs required to set up these clinics.
Disability was assessed at 6 months and was defi ned as an mRS score between 3 and 5 points. Because patients could have been disabled before their index event, new disability combined with death at 6 months was also assessed. New disability was defi ned as the progression between no disability before event (ie, pre-event mRS score <3 points) to disability 6 months after index event (ie, 6-month mRS score >2 points).
Admissions to hospital, day cases, and length of stay were derived from central administrative sources, patients' records, and direct questioning at follow-up, which provided information on the dates of admission and discharge, and on patient transfers between specialty wards. The causes of admission to hospital were investigated by hot pursuit or by matching event dates to admission dates, linking of hospital information with discharge coding, and by a review of hospital notes by the OXVASC senior neurologist (PMR). Unit costs were obtained from national reference costs and calculated for each day spent in each specialty ward. 13, 21, 22 Costs were standardised to 2005-06 prices by use of the UK National Health Service hospital and community health services infl ation index. Unit costs, length of stay by ward type, and number of day cases in each phase of EXPRESS are reported in webtables 1 and 2.
Categorical outcomes, including admissions to hospital and disability, are reported as proportions, and exact 95% CIs were calculated. In addition, for these variables, the size of eff ect was reported as an odds ratios with 95% CIs. Statistical diff erences for categorical variables were evaluated with standard χ² tests. Hospital bed-days and costs were reported as means. To account for the skewed resource use and cost data, 95% CIs were calculated non-parametrically from 10 000 bootstrap estimates. 23 To assess the main predictors of hospital vascular admission-hospital bed-days and total costs-a two-part model was used. A logistic regression model was used to assess the predictors of admission to hospital. Conditional on admission, a general gamma linear model assuming a log identity was used to determine baseline predictors of length of stay and costs of hospital admission at the 90-day follow-up. 24 Logistic multivariate analyses were done to assess prognostic indicators of new disability or death, and overall disability or death, at 6 months. For the multivariate analysis of new disability or death, those patients who were already disabled before their index event were excluded from the analysis because the main objective was to record progression from either no baseline disability to disability or death, or baseline disability to death, 6 months after the event. Baseline predictors are sex; age; previous history of myocardial infarction, angina, peripheral vascular disease, hypertension, stroke, or diabetes; smoking status; age at which the patient left education; event type (TIA or stroke); stroke severity (NIHSS score); and disability before the event (mRS of 3 to 5 points). Both age and NIHSS score were included in the analyses as categorical variables because of observed non-linear eff ects on outcomes, resource use, and costs. 13 Further regression models were done that included age and NIHSS score as continuous variables, and by including the quadratic terms of age and NIHSS score. The results showed that the models were best specifi ed when age and NIHSS score were included as categorical variables. Statistical signifi cance was set at p<0·05. Diagnostic tests to check for model specifi cation were done with Preigbon's link test.
To assess the consequences of a decrease in the eff ectiveness of the phase 2 clinic on hospital bed-days and hospital costs, the 80% reduction in recurrent stroke risk achieved by urgent assessment and treatment in the phase 2 clinic was reduced to 40% (ie, half the eff ectiveness). We assumed that the observed relations between reductions in recurrent stroke risk during phase 2 and the eff ect on length of stay and costs would be the same. Although most TIA and minor strokes were referred to the EXPRESS study clinic, a proportion of patients with TIA and minor stroke (NIHSS score ≤3 points) were managed by their primary-care physicians, referred to hospital-based care, or referred to other specialist clinics. A further sensitivity analysis was therefore done that included all patients with TIA and minor stroke who were not referred to the EXPRESS clinic. For this analysis, we compared the number of recurrent strokes, progression to disability or death, number of admissions to hospital due to vascular causes, hospital bed-days because of vascular admissions, and associated costs of admission to hospital in phase 1 with those in phase 2, using the methods described above.
Role of the funding source
None of the agencies that funded OXVASC had any input into the design, performance, analysis, or reporting of either the OXVASC or EXPRESS studies, nor did they see the manuscript before fi nal acceptance for publication. RL-F, AMG, and PMR had access to all the data in the study and had fi nal responsibility for the decision to submit the manuscript for publication.
Results
In the whole OXVASC population, 634 patients sought medical attention after TIA or stroke in phase 1 and 644 in phase 2 (ie, 1278 fi rst presentations, with 66 patients seeking medical attention after an event in both phases). 607 presentations (285 in phase 1 and 322 in phase 2) were made directly to emergency services or were patients who were already in hospital at the time of stroke. Of the 620 patients with TIA or stroke who were referred to outpatient services, 591 (95%) were referred direct to the study clinic (310 in phase 1 and 281 in phase 2), and are the sample in our primary analysis (table 1) .
Baseline characteristics and risk factors of the patients, which have been reported elsewhere, 15 were generally similar in the two phases of the study (table 2) , including education levels (p=0·39) and mRS scores (p=0·13). The median (IQR) NIHSS score for the patients with minor strokes (ie, excluding patients with TIA) at the time of assessment in the study clinic was 1 (0-3) point in both study periods; 236 (86%) patients had NIHSS scores of 3 points or less and 264 (96%) had NIHSS scores of 5 points or less.
EXPRESS showed that attendance at the phase 2 clinic signifi cantly reduced the number of 90-day recurrent strokes compared with attendance at the phase 1 clinic Data are n (%) or mean (SD). *As part of these admissions to hospital one patient in each phase had carotid surgery. †Fisher's exact test. (table 3) . Event severity, as assessed by an NIHSS score greater than 3 points, (p=0·004) and being 75 years or older (p=0·02) were predictors of death or new disability at 6 months, after controlling for other baseline characteristics in the multivariate analysis. Assessment during phase 2 was signifi cantly associated with reduced new disability or death (p=0·03). Similarly, assessment in phase 2 was associated with reduced death or overall disability at 6 months (p=0·04). Event severity assessed by NIHSS score greater than 3 points (p=0·002) and previous disability (p<0·0001) were signifi cantly associated with increased overall disability or death, after controlling for baseline characteristics in the multivariate analysis (table 3) .
57 of 310 patients (18%) who were referred to the study clinic in phase 1 were admitted to hospital during the 90-day follow-up period, compared with 50 of 281 patients (18%) during phase 2 (p=0·85; table 4). No signifi cant diff erences in reasons for admission to hospital were found between phases, except for recurrent strokes: 25 of 310 patients (8%) in phase 1 compared with 5 of 281 patients (2%) in phase 2 (OR 0·21, 95% CI 0·88-0·55; p=0·001). There were substantially fewer bed-days in phase 2 than in phase 1: 672 bed-days in phase 2 compared with 1957 bed-days in phase 1 (table 4), which translated into an average reduction of four (95% CI -8 to -1; p=0·02) hospital bed-days per patient referred to the clinic in phase 2 compared with phase 1.
The number of days in hospital due to any vascular disease was lower in phase 2 than in phase 1 (427 vs 1365 days, respectively; a mean reduction of 3 days per patient, 95% CI -6 to -1; p=0·02). Table 5 shows that the reduction in days in hospital during phase 2 was driven by reductions in days in hospital due to recurrent stroke, whereas days in hospital because of other vascular causes did not vary signifi cantly between phases. Conditional on hospital admission, the length of stay for patients who were admitted in phase 1 was 29 (SD 52) days compared with 11 (11) days for those admitted in phase 2, which is a reduction of 18 days (95% CI -36 to -4; p=0·02) per patient. Furthermore, patients who had recurrent stroke in phase 2 had shorter stays than did those who had recurrent stroke in phase 1; the mean length of stay was 15 (29) days in phase 2 compared with 32 (60) days in phase 1, a non-signifi cant mean reduction of 17 days (-46 to 20; p=0·37).
Because the study clinics in phase 1 and phase 2 were undertaken over diff erent time periods, external factors could explain some of the diff erences in length of stay between phases. Hospital admissions for the 607 patients who attended emergency services and were referred directly for inpatient treatment or were in hospital at the time of event were, therefore, also assessed. There were no diff erences in length of stay between the two phases (31 days; p=0·89), which suggests that unmeasured temporal trends did not aff ect the length of overall hospital stay during the two time periods. Table 5 shows the average hospital costs incurred as a result of vascular causes in each phase. In phase 1, the average costs per patient were £1056 (SD £4879) compared with £432 (£2277) in phase 2, a reduction of £624 (95% CI £1370 to £104; p=0·03) per patient. The reduction in hospital costs during phase 2 was generated by substantial reductions in costs due to recurrent stroke. For patients with recurrent stroke, the mean hospital cost incurred (total cost of recurrent stroke averaged by number of patients who had recurrent stroke [n=38]) was £7449 (£12 444) in phase 1 compared with £3560 (£6394) in phase 2, an average reduction of £3888 (-£9937 to £4087; p=0·326).
Most patients (484 of 591 [82%]) were not admitted to hospital, and therefore did not incur any hospital-related costs. A two-part regression model was used to ascertain the baseline predictors of hospital admission for vascular Data are n, mean (SD), or diff erence (95% CI). *To obtain p values, the total number of days in hospital was averaged by the total patient sample. reasons (if patients incurred hospital-related costs), hospital bed-days, and hospital-related costs (table 6) . A history of peripheral vascular disease (p=0·005) and severity of stroke (p<0·0001), defi ned as an NIHSS score higher than 3 points, were predictors of overall hospital admission, after controlling for baseline characteristics in the multivariate analysis. Results from the multivariate analysis also showed that, conditional on hospital admission, attendance at the phase 2 clinic was signifi cantly associated with reduced length of stay and hospital-related costs, whereas premorbid disability was signifi cantly associated with increased length of stay and hospitalrelated costs (table 6) . Of the 1278 (634 in phase 1 and 644 in phase 2) presentations for medical attention after TIA or stroke (table 1) , 966 patients (476 in phase 1 and 490 in phase 2) sought medical attention for TIA or minor stroke, and the rest (312 patients [158 in phase 1 and 154 in phase 2]) sought medical attention for a more severe stroke. Of the 966 TIA or minor strokes, 620 (323 in phase 1 and 297 in phase 2) were referred for outpatient assessment, of which 591 (95%) were referred to the EXPRESS clinics. The remaining 346 patients (153 in phase 1 and 193 in phase 2) with TIA or minor stroke were referred elsewhere (mostly to an emergency department or directly to hospital for acute admission). A sensitivity analysis was done by including all patients with TIA and minor stroke, irrespective of whether or not they were referred to the EXPRESS clinic. This was done to identify whether attendance at the phase 2 EXPRESS clinic reduced progression to death or disability, admissions to hospital due to vascular causes, hospital bed-days, and associated costs for all patients with TIA or minor stroke.
476 patients with TIA or minor stroke (233 TIA, 243 minor stroke) in phase 1 and 490 patients (251 TIA, 239 minor stroke) in phase 2 sought medical attention. During phase 1, 139 of 476 patients (29%) were admitted to hospital for vascular reasons compared with 156 of 490 patients (32%) in phase 2 (p=0·37). The number of days in hospital because of any vascular disease was lower in phase 2 than in phase 1 (4520 days vs 3728 days). When averaged across all patients, the mean number of hospital bed-days was 10 (SD 37) days in phase 1 compared with 8 (25) in phase 2, a mean reduction of 2 days (95% CI -6 to 2; p=0·176). Conditional on hospital admission, the average length of stay was 33 (62) days in phase 1 compared with 24 (41) days in phase 2 (mean diff erence -9 days, 95% CI -22 to 3; p=0·079). In phase 1, the mean costs of treatment in hospital were £2646 (£11 848) compared with £2124 (£6642) in phase 2, a non-signifi cant diff erence of -£522 (-£1989 to £554; p=0·13) per patient. For patients admitted to hospital, the mean cost was £9062 (£20 606) in phase 1 compared with £6670 (£10 425) in phase 2, a mean diff erence of -£2392 (-£6684 to £791; p=0·10).
The main analysis of the EXPRESS study showed an 80% reduction in recurrent stroke risk in phase 2 compared with phase 1. However, if we assume the same relation between reductions in recurrent stroke risk and hospital costs and bed-days, halving the eff ectiveness rate of the phase 2 clinic (ie, a 40% reduction in stroke risk) would be associated with a 33% reduction in hospital bed-days (2·95 days vs 4·4 days in phase 1), and a 30% reduction in costs of hospital admission (£744 vs £1056 for phase 1).
Discussion
In the UK, most patients with TIA or minor stroke are managed in weekly outpatient clinics after referral by a primary-care physician. This system results in about half of all patients waiting for more than 14 days to be assessed and treated, 14 during which time the risk of recurrent stroke is at its highest. The EXPRESS study showed that urgent assessment of TIA and minor stroke in combination with early initiation of preventive treatment This further analysis shows that, for patients referred to the EXPRESS study outpatient clinic, there were also reductions in fatal or disabling recurrent strokes, 90-day hospital bed-days, costs of admission to hospital, and overall disability levels at 6 months' follow-up. Furthermore, those patients in phase 2 who had recurrent stroke spent less time in hospital, incurred lower costs, and had lower case fatality and new disability rates than the patients in phase 1; however, the number of recurrences during phase 2 was too small to assess the diff erences reliably. We report that urgent assessment and treatment of TIA and minor stroke reduced the overall number of days in hospital and generated savings of £624 per patient referred to the clinic. The extrapolation of these results across a population of 1 million individuals would equate to the prevention of about 165 strokes annually and save the health service 4790 hospital bed-days, with monetary savings of £1·12 million. For the UK as a whole, this would prevent about 10 000 strokes annually, and would generate savings of 290 000 hospital bed-days and monetary savings of £68 million in acute care costs alone. In addition, the reductions in disability rates at 6 months might lead to a reduction in the long-term usage of the health service in the community. The phase 2 clinic costs, which are not included in these results, are likely to be a small proportion of the savings.
This rigorous study investigated the eff ect of urgent assessment and treatment of TIAs and strokes that do not require immediate admission to hospital on hospital admissions, hospital bed-days, and the associated costs. As discussed in the main EXPRESS study paper, 15 the random assignment of individuals was not feasible because patients would not consent to delayed specialist assessment and treatment. Nevertheless, we would argue that the EXPRESS study produced results that are reliable and convincing, and that EXPRESS should not be confused with studies that have historical controls (ie, the control group is chosen retrospectively), which have the potential for incomplete ascertainment of cases and the introduction of selection bias. By contrast, the control group in the EXPRESS study was prospectively recruited in phase 1 and included all patients who presented for medical attention in the whole study population, which minimised any potential for selection bias.
There was also little evidence of other sources of bias. 15 First, there was no signifi cant temporal change in the rates of referral to the EXPRESS clinic. Second, there was no change in the delay before seeking medical attention after a TIA or minor stroke or in the number of patients who had early recurrent stroke before seeking medical attention. Third, there was no change in the methods (or effi ciency) of either our face-to-face follow-up of patients or our daily ascertainment of all strokes in the population. Fourth, there was no change in our defi nition of recurrent stroke, and all outcomes were independently audited at the end of the study by assessors who were blinded to the phase of the study. There was also no evidence of confounding by factors that in addition to the study intervention had changed between phase 1 and phase 2. We have reliable evidence of stability in the early risk of recurrent stroke in our study population, which we have studied over the past two decades by comparison of phase 1 of the study with a similar population-based study in the same primary care practices done between 1981 and 1986. 15 The recurrence rates in phase 2 changed immediately in October, 2004, when the new clinic was introduced, rather than slowly over the 5 years of the study. There was also no substantial change in the characteristics of the patients who presented with TIA or stroke between the two periods, apart from a small increase in the proportion on premorbid statin treatment, mainly because of the re-presentation of patients who were treated in phase 1. Additionally, we found attendance at the phase 2 clinic to be signifi cantly associated with a reduction in days in hospital, costs of admission to hospital, and progression to disability or death, after controlling for other baseline characteristics in multivariate analyses.
Although the treatment eff ect was large (an 80% relative reduction in 90-day risk of stroke), an eff ect of this size was consistent with previous studies that modelled the probable eff ect of combined treatment modalities on secondary prevention after TIA or stroke, 9 and was plausible in light of the substantial diff erence in delay to prescription of treatment between the two phases of EXPRESS. 15 The median time from the seeking of medical attention to fi rst prescription of one of the treatments recommended in the faxed letter from the study clinic to the primary-care physician in phase 1 (statin, blood pressure-lowering drug, clopidogrel, or warfarin) was 19 (IQR 6-48) days. The equivalent delay in phase 2 was 1 day (0-3 days; p<0·0001) because treatment was initiated in the study clinic. 15 Therefore, this study compared intensive treatment with minimal treatment during the fi rst few high-risk days and weeks after TIA and minor ischaemic stroke. Furthermore, in contrast with the populations recruited in most randomised controlled trials, 25 our population-based study included many older patients (a third were ≥80 years).
However, our study did have some limitations in addition to being non-randomisied. External biases, such as changes in health policy or management between the two phases, in theory could explain the reductions in hospital stay and associated costs. However, we found that hospital admissions for non-recurrent stroke, length of stay, and costs did not diff er between phases, and for patients who presented directly to hospital inpatient services, rather than to the EXPRESS study clinic, patterns of resource use were the same during the two phases.
We assessed hospital-related costs and disability only over a short period (ie, 90 days and 6 months after an event, respectively). As a result, the long-term consequences of urgent assessment and treatment are unknown. The 90-day follow-up period for resource use was chosen to be consistent with the duration of follow-up in the eff ectiveness study, 15 whereas the 6-month follow-up period for disability was used because mRS data were not collected at 90 days because recovery from stroke often continues beyond 90 days. Published studies have also shown that most of the costs of admission to hospital are accrued in the months shortly after stroke, and the costs of further admissions to hospital are small. [26] [27] [28] [29] Process of care outcomes, such as hospital admission, are potentially more prone to bias in non-randomised studies (or non-blinded randomised studies) because such decisions might be infl uenced by knowledge of previous treatments. For example, physicians in phase 2 could have worked harder not to admit patients with symptoms of minor stroke to hospital; however, as shown in table 4, overall rates of admissions to hospital were similar in both phases. Only admissions to hospital for recurrent stroke were signifi cantly lower in phase 2 than they were in phase 1, which was because of signifi cantly fewer recurrent strokes in phase 2. Of the six recurrent strokes in phase 2, fi ve patients (83%) were admitted to hospital, compared with 25 of 32 patients (78%) with recurrent stroke in phase 1; in fact, admissions for reasons other than recurrent stroke were non-signifi cantly higher in phase 2 (table 4) .
To assess the eff ect of the EXPRESS study clinic intervention on outcome in patients with TIA and minor stroke, our primary analysis was restricted to 591 patients who were referred to the study clinic, and excluded 375 patients with TIA or minor stroke who were referred elsewhere (mainly to an emergency department or for acute admission to hospital). However, we also did a sensitivity analysis that included all patients with TIA or minor stroke, which showed reductions in the 90-day risk of recurrent stroke in phase 2 compared with phase 1 and the number of patients that progressed to death or disability at 6 months. However, in phase 2, the reductions in hospital bed-days for vascular causes and the associated costs were no longer statistically signifi cant, which is not unexpected in light of the dilution of the eff ect of the study intervention by the inclusion of additional patients who were admitted directly to hospital after their initial TIA or stroke.
We did not quantify the costs to the health service of setting up outpatient clinics for the urgent assessment and treatment of TIA and minor stroke. The phase 2 clinic was set up as part of the OXVASC research study, and what part of these costs might be incurred in routine practice to reduce waiting times for patients with TIA or minor stroke was not clear. However, OXVASC did not incur any additional costs during phase 2 in terms of additional clinical staff or administrative support. The only observable additional cost during phase 2 was the cost of the extra medication, because patients in this phase were started on medication earlier than were the patients in phase 1. Nevertheless, the introduction of outpatient clinics would involve additional costs to the health service.
Recent guidelines published by the UK National Institute for Health and Clinical Excellence (NICE) on stroke and TIA management 30 cite unpublished evidence that outpatient clinics that off er urgent care and treatment for patients with TIA or minor stroke generate additional costs of £94 per patient compared with a weekly clinic (£410 vs £316). Therefore, if the additional cost of setting up an EXPRESS phase 2 clinic was similar to that reported by NICE, these additional costs would not negate the savings in hospital bed-days and costs (£624 per patient) associated with urgent assessment and treatment of patients with TIA and minor stroke, or the potential savings in community care costs due to reduced disability rates. In addition, even if the eff ectiveness of the phase 2 clinic in reducing 90-day recurrent stroke risk were to fall to 40%, the additional costs of setting up the phase 2 clinic would not negate the savings of £212 per patient in the costs of treatment in hospital that are generated by the urgent assessment clinic.
Our results are likely to be conservative because, in current average UK practice, many patients with TIA and minor stroke wait more than 14 days to be assessed, investigated, and treated, 14 compared with the 3-day delay between fi rst event and specialist assessment in phase 1 of EXPRESS. 15 In conclusion, we show that, irrespective of the characteristics of patients, early assessment and initiation of treatment in patients with TIA or minor stroke not only reduced the risk of early recurrent stroke by 80%, but also reduced hospital admissions, hospital bed-days, costs of acute admissions to hospital, and disability rates in patients referred to the outpatient specialist clinics. Further followup is needed to assess the long-term outcome, costs, and, therefore, long-term cost-eff ectiveness of early assessment and treatment, but these short-term results suggest that a service provision for TIA and minor stroke that is similar to that in phase 2 of the EXPRESS study is likely to be costeff ective.
Contributors RL-F obtained the resource use and cost data, was responsible for data management, did the analyses, and wrote the manuscript. AMG supervised the economic analysis, provided direct input into the interpretation of results, and revised, edited, and decided on the fi nal content of the manuscript. PMR designed and ran the OXVASC and EXPRESS studies, obtained funding, reviewed all cases referred to the EXPRESS study clinic, provided direct input into the analysis and interpretation of results, and revised, edited, and decided on the fi nal content of the manuscript.
Confl icts of interest
PMR has received honoraria for talks, payment for occasional consultancy, or research funding from Sanofi -Aventis, Bristol-Myers Squibb, Servier, Bayer, and Boehringer Ingelheim, which manufacture drugs used in secondary prevention of stroke. RL-F and AMG have no confl icts of interest.
Research Council, the Dunhill Medical Trust, the Stroke Association, the BUPA Foundation, the National Institute for Health Research, the Thames Valley Primary Care Research Partnership, and the Oxford Partnership Comprehensive Biomedical Research Centre. We are also grateful to the other contributors to the study, who are listed elsewhere.
